Press Releases
All Pfizer published press releases by date and/or category of news
-
01.03.2019 Research Pfizer Initiates Phase 2b/3 Clinical Trial for PF-06651600, an Oral JAK3 Inhibitor, for the Treatment of Patients with Moderate to Severe Alopecia Areata -
12.21.2018 Research Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer -
12.20.2018 Research Vaccines Independent Data Monitoring Committee Recommends Discontinuation of the Phase 2b STRIVE Clinical Trial of Staphylococcus aureus Vaccine Following Planned Interim Analysis -
12.20.2018 Research Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer -
12.14.2018 Research Vaccines Pfizer Initiates Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older -
12.02.2018 Research Pfizer Presents Positive 26-Week Data For PF-05280586, A Potential Biosimilar To Rituximab, At The American Society Of Hematology Annual Meeting -
11.19.2018 Research Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer -
10.28.2018 Research Pfizer Announces Clinical Development Agreement with Novartis to Advance the Treatment of NASH -
10.23.2018 Research Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients -
10.20.2018 Research Pfizer Presents Overall Survival Data From PALOMA-3 Trial of IBRANCE® (palbociclib) in Patients With HR+, HER2- Metastatic Breast Cancer -
09.18.2018 Research New Sub-group Analyses from the Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Presented at 2018 HFSA Annual Scientific Meeting -
09.14.2018 Research Pfizer Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at the 27th European Academy of Dermatology and Venereology (EADV) Congress
Trust in Technology – A Snapshot
Pfizer surveyed adults in 10 countries across the Global North and South to better understand the general population's trust in incorporating technology into the management of their healthcare. The results showed that 6 in 10 trust technology in this setting but that means 4 in 10 are at risk of being left behind. Our findings underscored that patients won’t feel the full benefits of that technology if we don’t have trusted people – specifically health care providers – delivering it. We must partner with patients, healthcare providers, policy makers and others in the life sciences and tech industries to build trust in the technologies that are fueling the future of health.
Media Asset Library
A collection of assets for use by media.
Updates and Statements
Partnering News
The latest news from Pfizer and its strategic partners
-
01.11.2022 Partnerships Dren Bio Announces Research Collaboration and License Agreement with Pfizer to Discover and Advance Multiple Therapeutic Antibodies Using its Targeted Myeloid Engager and Phagocytosis Platform for the Treatment of Cancer -
12.16.2021 Partnerships Anaveon to raise CHF 110 million in oversubscribed Series B financing
Media Contacts
Pfizer Media Relations
We encourage everyone to view our press releases, press statements, and press kits to stay up to date on Pfizer news.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.
Media Contacts
General email
[email protected]
United States, Canada and Latin America
+1 212.733.1226
Europe, the Middle East and Africa
+44-(0)173.733.2335
[email protected]
Asia Pacific
+65.918.732.47
What we need
To best help us help you, please be prepared to provide your name and email address, a summary of the article you're working on and your deadline.
Other Frequently Visited Links
For more, see these helpful and often used sections of Pfizer.com
Pfizer Wire
Stay up to date on the latest news and alerts through the Pfizer Wire
Sign up to receive real-time updates on Pfizer’s news from the Pfizer Media Relations team delivered directly to your inbox.